/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ranibizumab proves instrumental for DME patients in RIDE, RISE trials

    Provided improved visual acuity, diabetic retinopathy remained stable over the long-term


    “The PRN ranibizumab treatment during the extension phase continues to reduce the occurrence of new PDR events and patients continued to show improvement in DR with PRN ranibizumab,” Dr. Elman added.

    A new PDR event was defined as the first occurrence of progression from nonproliferative DR to PDR, use of panretinal laser, occurrence of vitreous hemorrhage, identification by ophthalmoscopy, vitrectomy for PDR, and occurrence of iris or retinal neovascularization.

    Looking at patients with the longest follow-up at months 36 and 60, 49% and 40% of patients, respectively, had improvements of two or more ETDRS steps and 21% and 11% had improvements of three or more ETDRS steps.

    “The population of the RIDE and RISE studies represents the entire spectrum of DR,” Dr. Elman summarized. “Improvement over sham in DR was seen as early as month 3 after the onset of treatment with ranibizumab for two or more steps of improvement or at month 12 for three or more steps of improvement. The improvement in DR was maintained with as-needed administration of ranibizumab.”


    Michael J. Elman, MD

    E: [email protected]

    This article was adapted from Dr. Elman’s presentation at the 2015 meeting of the Association for Research in Vision and Ophthalmology. Dr. Elman receives financial support from Genentech

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results